These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34637126)

  • 41. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
    Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
    J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
    Zhou X; Chen Z; Bi X
    Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
    Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
    Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Uptake of rheumatology biosimilars in the absence of forced switching.
    Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
    Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
    Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
    BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI; Fitzpatrick RW; Chapman SR
    BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.
    Schiff MH; Burmester GR; Kent JD; Pangan AL; Kupper H; Fitzpatrick SB; Donovan C
    Ann Rheum Dis; 2006 Jul; 65(7):889-94. PubMed ID: 16439435
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade
    Xue L; van Bilsen K; Schreurs MWJ; van Velthoven MEJ; Missotten TO; Thiadens AAHJ; Kuijpers RWAM; van Biezen P; Dalm VASH; van Laar JAM; Hermans MAW; Dik WA; van Daele PLA; van Hagen PM
    Front Med (Lausanne); 2020; 7():418. PubMed ID: 32850911
    [No Abstract]   [Full Text] [Related]  

  • 49. How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
    Marcianò I; Ingrasciotta Y; Giorgianni F; Bolcato J; Chinellato A; Pirolo R; Di Giorgio A; Manna S; Ientile V; Gini R; Santarpia M; Genazzani AA; Uomo I; Pastorello M; Pollina Addario SW; Scondotto S; Cananzi P; Da Cas R; Traversa G; Rossi M; Sottosanti L; Caputi AP; Trifirò G
    BioDrugs; 2016 Aug; 30(4):295-306. PubMed ID: 27138636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.
    Phan DB; Jourdain H; González-Quesada A; Zureik M; Rivera-Díaz R; Sahuquillo-Torralba A; Descalzo-Gallego MA; Lunt M; Garcia-Doval I; Sbidian E; Warren RB; Yiu ZZN
    BMJ Open; 2023 Jul; 13(7):e075197. PubMed ID: 37451726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.
    Winthrop KL; Chen L; Fraunfelder FW; Ku JH; Varley CD; Suhler E; Hills WL; Gattey D; Baddley JW; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Herrinton LJ; Fraunfelder FT; Saag KG; Lewis JD; Solomon DH; Curtis JR
    Am J Ophthalmol; 2013 Jan; 155(1):183-189.e1. PubMed ID: 22967869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel approach to support implementation of biosimilars within a UK tertiary hospital.
    Saxby K; Sanghvi S; Bodalia PN; Ferner RE; Leandro M; Urquhart R; Sofat R
    Br J Clin Pharmacol; 2020 Jan; 86(1):23-28. PubMed ID: 31663154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
    Kim SC; Choi NK; Lee J; Kwon KE; Eddings W; Sung YK; Ji Song H; Kesselheim AS; Solomon DH
    Arthritis Rheumatol; 2016 May; 68(5):1076-9. PubMed ID: 26662931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.
    Leonardi C; Papp K; Strober B; Thaçi D; Warren RB; Tyring S; Arikan D; Karunaratne M; Valdecantos WC
    Br J Dermatol; 2019 Jan; 180(1):76-85. PubMed ID: 30169904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
    Fiorino G; Girolomoni G; Lapadula G; Orlando A; Danese S; Olivieri I;
    Autoimmun Rev; 2014 Jul; 13(7):751-5. PubMed ID: 24657898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    Sci Rep; 2022 Nov; 12(1):19569. PubMed ID: 36380105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
    Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
    [No Abstract]   [Full Text] [Related]  

  • 59. Biosimilars for the treatment of psoriatic arthritis.
    Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
    [No Abstract]   [Full Text] [Related]  

  • 60. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.